Why Medical Cannabis Is Not Available on the NHS

Introduction

Medical cannabis was legalised in the United Kingdom on 1 November 2018. It was a moment that generated enormous hope among patients with chronic pain, epilepsy, multiple sclerosis, and dozens of other conditions. Yet more than seven years later, the reality for most patients is stark: the NHS has issued fewer than 10 medical cannabis prescriptions in total. The overwhelming majority of the estimated 1.4 million people in the UK who use cannabis for medical purposes obtain it illegally or pay for private prescriptions costing hundreds of pounds per month.

This article explains why the NHS has effectively failed to implement the 2018 legalisation, what the barriers are, and what patients can do to access treatment legally.

What Changed in 2018?

On 1 November 2018, the UK government rescheduled cannabis-based medicinal products (CBMPs) from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. This change made it legal for specialist doctors — specifically, those on the GMC Specialist Register — to prescribe CBMPs for any condition where there is a clinical need.

Crucially, the change did not make medical cannabis available on the NHS. It made it prescribable — a subtle but enormously consequential distinction. For an NHS prescription to be issued, the treatment must also be approved by the National Institute for Health and Care Excellence (NICE) and funded by NHS England or the relevant integrated care board (ICB).

Why Won't the NHS Fund It?

The NHS's reluctance to fund medical cannabis prescriptions comes down to several interconnected factors:

1. NICE Has Not Approved Most Indications

NICE evaluates treatments based on clinical and cost-effectiveness evidence. For the vast majority of conditions for which medical cannabis is prescribed privately — chronic pain, PTSD, anxiety, insomnia, ADHD — NICE has not found sufficient evidence from randomised controlled trials (RCTs) to recommend NHS funding.

NICE has approved only three cannabis-based medicines for NHS use:

• Epidyolex (cannabidiol) — for Dravet syndrome and Lennox-Gastaut syndrome (severe childhood epilepsies)

• Sativex (nabiximols) — for spasticity in multiple sclerosis, but only in Scotland via the Scottish Medicines Consortium; NHS England has not approved it

• Nabilone — a synthetic cannabinoid for chemotherapy-induced nausea, available in limited circumstances

Everything else — the broad range of CBMPs prescribed by private clinics — falls outside NICE approval and is therefore not routinely funded by the NHS.

2. The Evidence Gap

The fundamental problem is that the evidence base for medical cannabis comes primarily from observational studies, patient registries, and open-label trials — not the double-blind, placebo-controlled RCTs that NICE requires for approval. This is partly a consequence of cannabis's Schedule 1 status for decades, which made research extremely difficult, and partly a reflection of the commercial reality that pharmaceutical companies have little incentive to fund expensive trials for a product that cannot be easily patented.

The UK Medical Cannabis Registry (UKMCR), run by Drug Science, has generated valuable real-world evidence, but observational data alone is not sufficient for NICE approval.

3. Clinical Conservatism

Many NHS consultants — the only clinicians legally able to prescribe CBMPs — are reluctant to do so. Reasons include:

• Lack of training in cannabinoid medicine

• Concerns about professional liability

• Uncertainty about dosing and product selection

• The absence of NICE guidance for most conditions

• Fear of GMC scrutiny

The result is that even patients who clearly meet the clinical criteria for a CBPM prescription often cannot find an NHS consultant willing to prescribe.

4. NHS Funding Gatekeeping

Even where a consultant is willing to prescribe, NHS funding must be obtained separately. For most patients, this means applying to their ICB for an Individual Funding Request (IFR) — a process that is time-consuming, uncertain, and rarely successful for cannabis-based treatments.

The Human Cost

The gap between legalisation and access has real human consequences. Patients who cannot afford private prescriptions — which typically cost £200–£500 per month — face a stark choice: continue using illegal cannabis (and risk criminalisation), go without treatment, or struggle with inadequate conventional alternatives.

A 2023 survey by the patient advocacy group PLEA found that 83% of medical cannabis patients in the UK had used illegal cannabis before obtaining a private prescription. The same survey found that 74% said they could not afford to maintain their private prescription indefinitely.

What Can Patients Do?

For patients who cannot access medical cannabis through the NHS, the options are:

1. Private prescription — the most common route, via a specialist medical cannabis clinic. Costs vary significantly between clinics. 2. CPGUK support — CPGUK provides free guidance on accessing private prescriptions and can help patients understand their options and find appropriate clinical support. 3. Clinical trials — a small number of NHS-funded clinical trials are investigating medical cannabis for specific conditions. CPGUK can help patients identify relevant trials. 4. Advocacy — organisations including PLEA, Drug Science, and CPGUK are actively campaigning for improved NHS access. Patient voices matter in this debate.

MEDCANN Pharmacy, CPGUK's most recommended clinic operator in 2026, offers transparent pricing and a streamlined prescribing process for patients seeking private medical cannabis prescriptions. As a GPhC-registered pharmacy with an integrated clinical service, MEDCANN Pharmacy provides both the consultation and the dispensing under one roof — reducing cost and complexity for patients. Visit medcannpharmacy.co.uk to find out more.

Conclusion

Medical cannabis is legal in the UK but effectively inaccessible through the NHS for the vast majority of patients. The barriers — NICE's evidence requirements, clinical conservatism, and funding gatekeeping — are real and unlikely to be resolved quickly. In the meantime, private prescriptions remain the primary route to legal access, and CPGUK is here to help patients navigate that process as affordably and effectively as possible.